Lung Non-Small Cell Carcinoma with Genetic Abnormalities

Lung Non-Small Cell Carcinoma with Genetic Abnormalities — Trials · CancerIndex

Clinical trials

Registered studies

31 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.

Active: 10
Recruiting: 5
Ph III recruiting: 0
Growth YoY: —
Industry share: 50%
Top sponsor: Guangdong Association of Clinical Trials
Termination share: —

Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancers Terminated studies (5)

clinicaltrialsPublishedShowing 1–2 of 2 studies matching the filters · status and phase as posted by the registrant; each row links to the study record.

NCT	Title	Status	Phase	Enrollment (n)	Sponsor	Countries	Last update	Source
NCT04203485	Camrelizumab Combined With Apatinib Mesylate or Camrelizumab Alone for First-line Treatment in Subjects With Programmed Death Ligand 1 (PD-L1) Positive Relapsed or Advanced Non-small Cell Lung Cancer (NSCLC)	unknown	Phase 3	762	Jiangsu HengRui Medicine Co., Ltd.INDUSTRY	0	May 8, 2020	clinicaltrials
NCT04009317	Study of TQ-B3139 Versus Crizotinib in the First Line Treatment of Subjects With Anaplastic Lymphoma Kinase (ALK) Positive Non-Small Cell Lung Cancer (NSCLC)	unknown	Phase 3	260	Chia Tai Tianqing Pharmaceutical Group Co., Ltd.INDUSTRY